Abstract:Ana RS Ribeiro, 1, 2 Theresa Neuper, 1– 3 Jutta Horejs-Hoeck 1– 3 1 Department of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, Austria; 2 Cancer Cluster Salzburg (CCS), Salzburg, 5020, Austria; 3 Center for Tumor biology and Immunology (CTBI), Salzburg, 5020, Austria Correspondence: Jutta Horejs-Hoeck, Department of Biosciences and Medical Biology, Paris-Lodron University Salzburg, Hellbrunner Strasse 34, Salzburg, 5020, Austria, Tel +43(0)662 8044 5709, Email The signaling pathway that comprises cyclic guanosine monophosphate–adenosine monophosphate (cGAMP or GMP-AMP) synthase (cGAS) and Stimulator of Interferon Genes (STING) is emerging as a druggable target for immunotherapy, with tumor-resident dendritic cells (DC) playing a critical role in mediating its effects. The STING receptor is part of the DNA-sensing cellular machinery, that can trigger the secretion of pro-inflammatory mediators, priming effector T cells and initiating specific antitumor responses. Yet, recent studies have highlighted the dual role of STING activation in the context of cancer: STING can either promote antitumor responses or enhance tumor progression. This dichotomy often depends on the cell type in which cGAS-STING signaling is induced and the activation mode, namely acute versus chronic. Of note, STING activation at the DC level appears to be particularly important for tumor eradication. This review outlines the contribution of the different conventional and plasmacytoid DC subsets and describes the mechanisms underlying STING-mediated activation of DCs in cancer. We further highlight how the STING pathway plays an intricate role in modulating the function of DCs embedded in tumor tissue. Additionally, we discuss the strategies being employed to harness STING activation for cancer treatment, such as the development of synthetic agonists and nano-based delivery systems, spotlighting the current techniques used to prompt STING engagement specifically in DCs. Keywords: dendritic cell, cGAS-STING pathway, cancer immunotherapy, nanoparticle The paradigm of natural antitumor immunity involves the recognition, processing and presentation of cancer-associated antigens by dendritic cells (DCs) on major histocompatibility (MHC) complexes, triggering effective T cell-mediated antitumor immunity that results in killing of the cancer cells. 1–4 Accordingly, DCs are highly specialized tissue-scanning cells equipped with a plethora of receptors to detect damage- or pathogen-associated molecular patterns (DAMPs or PAMPs). Although the immune system's task of filtering and responding to onco-signals emanating from cancerous tissue is an exceedingly complex one, the wide range of innate receptors expressed by DCs enables them to effectively recognize several by-products associated with tumor growth, such as tumor-derived DNA present in the tumor microenvironment (TME). 5–7 The cGAS-STING pathway is an innate DNA-sensing mechanism which was originally described to mediate protective immune responses against infections but was recently found to play a crucial role in driving antitumor immunity. In particular, activation of STING signaling in DCs has the potential to generate spontaneous as well as long-lasting and highly specific antitumor immunity. 8–10 This review focuses on the contribution of individual DC subsets to cancer defense and explores emerging developments in STING-mediated activation of DCs for novel cancer therapeutics. The cGAS-cGAMP-STING signaling pathway, discovered in 2013, is a promising therapeutic target to enhance antitumor immunity. Its activation induces an inflammatory response that converts "cold" tumors into "hot" tumors, ie, cancers that have higher infiltration of immune cells and consequently are more likely to exhibit higher response rates to currently used immunotherapies such as immune checkpoint inhibitors (ICI). 8,9,11 STING is a ubiquitous intracellular receptor that is located in the endoplasmic reticulum membrane and activated by binding of the agonist cGAMP. cGAMP is a naturally occurring cyclic dinucleotide (CDN) produced when the enzyme cGAS detects intracellular nucleic acids. Upon binding cGAMP, STING dimerizes and undergoes vesicular trafficking to the Golgi. This triggers downstream signaling which involves activation of TANK binding kinase 1 (TBK1), phosphorylation of interferon (IFN) regulatory factor 3 (IRF3), and induction of nuclear factor kappa B (NF-κB). 12,13 As a result, type I IFNs (IFN I) are upregulated, leading to expression and secretion of pro-inflammatory factors that can affect the TME and influence disease progression. 14–16 In cancer cells, the cGAS-STING pathway is frequently activated due to genomic instabi -Abstract Truncated-

STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity

Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma

CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of TH1 and TH9 cells

Synthetic Enforcement of STING Signaling in Cancer Cells Appropriates the Immune Microenvironment for Checkpoint Inhibitor Therapy.

STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment

STING-mediated DNA sensing in cancer immunotherapy

STING Licensing of Type I Dendritic Cells Potentiates Antitumor Immunity

Inhibition of anti-tumor immunity by melanoma cell-derived Activin-A depends on STING

STING agonists drive recruitment and intrinsic type I interferon responses in monocytic lineage cells for optimal anti-tumor immunity

Antagonism of regulatory ISGs enhances the anti-melanoma efficacy of STING agonists

STING signaling promotes NK cell antitumor immunity and maintains a reservoir of TCF-1+ NK cells

STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells

STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade

Synergistic innate immune activation and anti-tumor immunity through combined STING and TLR4 stimulation

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

EZH2 Inhibitor Enhances the STING Agonist‒Induced Antitumor Immunity in Melanoma

Systemic Administration of STING Agonist Promotes Myeloid Cells Maturation and Antitumor Immunity Through Regulating Hematopoietic Stem and Progenitor Cell Fate

Cell-to-cell communications of cGAS-STING pathway in tumor immune microenvironment.

The Role of STING-Mediated Activation of Dendritic Cells in Cancer Immunotherapy

Targeting STING signaling for the optimal cancer immunotherapy

STING, DCs and the link between innate and adaptive tumor immunity